市售吡柔比星注射液的血清代谢物

Q4 Pharmacology, Toxicology and Pharmaceutics

中国药理学通报 Pub Date : 2012-09-01 DOI:10.3969/J.ISSN.1001-1978.2012.09.025

W. Cong, Qingfei Liu, Qiong-lin Liang, G. Luo, K. Ruan, Yi Feng

{"title":"市售吡柔比星注射液的血清代谢物","authors":"W. Cong, Qingfei Liu, Qiong-lin Liang, G. Luo, K. Ruan, Yi Feng","doi":"10.3969/J.ISSN.1001-1978.2012.09.025","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the cumulative toxicity of commercial pirarubicin injection after 2 intravenous administrations on the normal sprague-dawley rats with serum metabonomics. Methods: The metabolic profiles of serum sample were obtained with ultra performance liquid chromatography coupled with time-of-flight mass spectrometry (UPLC/TOF-MS). The data were further processed with Masslynx software and analyzed with partial least squares discriminate analysis (PLS-DA). On the basis of a VIP (variable importance in projection) threshold of 1 from the 7-fold cross-validated PLS-DA model and student's test, potential biomarkers responsible for the difference in the metabolic profiles were obtained. Finally, they were identified by authentic standards or available databases. Results: It could be found that multiple dosages of THP would lead to fatty acids and phospholipids disturbance and severe cardiotoxicity via adriamycinone through the reactive oxygen species (ROS) mechanism. Conclusion: This study can provide a basis for the potential biomarkers screening of the cumulative cardiotoxicity of commercial pirarubicin injection in clinic.","PeriodicalId":10296,"journal":{"name":"中国药理学通报","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serum metabolites of commerical pirarubicin injections\",\"authors\":\"W. Cong, Qingfei Liu, Qiong-lin Liang, G. Luo, K. Ruan, Yi Feng\",\"doi\":\"10.3969/J.ISSN.1001-1978.2012.09.025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: To investigate the cumulative toxicity of commercial pirarubicin injection after 2 intravenous administrations on the normal sprague-dawley rats with serum metabonomics. Methods: The metabolic profiles of serum sample were obtained with ultra performance liquid chromatography coupled with time-of-flight mass spectrometry (UPLC/TOF-MS). The data were further processed with Masslynx software and analyzed with partial least squares discriminate analysis (PLS-DA). On the basis of a VIP (variable importance in projection) threshold of 1 from the 7-fold cross-validated PLS-DA model and student's test, potential biomarkers responsible for the difference in the metabolic profiles were obtained. Finally, they were identified by authentic standards or available databases. Results: It could be found that multiple dosages of THP would lead to fatty acids and phospholipids disturbance and severe cardiotoxicity via adriamycinone through the reactive oxygen species (ROS) mechanism. Conclusion: This study can provide a basis for the potential biomarkers screening of the cumulative cardiotoxicity of commercial pirarubicin injection in clinic.\",\"PeriodicalId\":10296,\"journal\":{\"name\":\"中国药理学通报\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国药理学通报\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3969/J.ISSN.1001-1978.2012.09.025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国药理学通报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3969/J.ISSN.1001-1978.2012.09.025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

目的:观察吡柔比星商用注射液2次静脉注射对正常大鼠血清代谢组学的累积毒性。方法:采用超高效液相色谱-飞行时间质谱法(UPLC/TOF-MS)测定血清代谢谱。采用Masslynx软件对数据进行进一步处理，并采用偏最小二乘判别分析(PLS-DA)进行分析。在7倍交叉验证PLS-DA模型和学生测试的VIP(投影变量重要性)阈值为1的基础上，获得了导致代谢谱差异的潜在生物标志物。最后，通过真实的标准或可用的数据库来确定它们。结果:多剂量THP可通过阿霉素的活性氧(ROS)机制引起脂肪酸和磷脂紊乱和严重的心脏毒性。结论:本研究可为吡柔比星市售注射液累积心脏毒性的潜在生物标志物筛选提供临床依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Serum metabolites of commerical pirarubicin injections

Aim: To investigate the cumulative toxicity of commercial pirarubicin injection after 2 intravenous administrations on the normal sprague-dawley rats with serum metabonomics. Methods: The metabolic profiles of serum sample were obtained with ultra performance liquid chromatography coupled with time-of-flight mass spectrometry (UPLC/TOF-MS). The data were further processed with Masslynx software and analyzed with partial least squares discriminate analysis (PLS-DA). On the basis of a VIP (variable importance in projection) threshold of 1 from the 7-fold cross-validated PLS-DA model and student's test, potential biomarkers responsible for the difference in the metabolic profiles were obtained. Finally, they were identified by authentic standards or available databases. Results: It could be found that multiple dosages of THP would lead to fatty acids and phospholipids disturbance and severe cardiotoxicity via adriamycinone through the reactive oxygen species (ROS) mechanism. Conclusion: This study can provide a basis for the potential biomarkers screening of the cumulative cardiotoxicity of commercial pirarubicin injection in clinic.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国药理学通报 Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

0.80

自引率

0.00%

发文量

11201

期刊介绍： Chinese Pharmacological Bulletin (CPB) is an academic monthly magazine sponsored by the Chinese Association for Science and Technology, the Chinese Pharmacological Society, and Anhui Medical University. Publicly issued domestically and internationally, CN:34:1086/R,ISSN:1001-1978。 The inclusion status of Chinese Pharmaceutical Bulletin (CPB): 1. This journal has been identified as a core medical journal by the China Science Citation Database (CSCD) of the Document Information Center of the Chinese Academy of Sciences (since 1993, there are 909 journals in the core library); 2. Selected as a pharmaceutical core journal by the editor in chief of Peking University Library's "Overview of Chinese Core Journals" (Peking University Core), 1st to 8th editions (1243 scientific and technological journals, including 232 medical and health journals); 3. Designated by the Institute of Science and Technology Information of the Ministry of Science and Technology of China as a source journal for Chinese scientific and technological paper statistics (China Science and Technology Core Journal); 4. Other: Domestic: Chinese Academic Journal Abstracts, Chinese Basic Medical Abstracts, Chinese Pharmaceutical Abstracts, Chinese Biological Abstracts, Chinese Academic Journals (CD version), Wanfang Database, VIP Database, etc; International: Chemical Abstract (USA), Corrective Bulletin on Science and Technology, CBST (Japan), Biological Abstract (USA), Biochemical Abstract (USA), EMBASE/Excerpta Medica (Netherlands), Index Copernicus (Poland), Kunst and Wissen (Germany), WPRIM (World Health Organization Western Pacific Regional Medical Index), Scopus (Netherlands, 2019 CiteScore 0.9), A&I (Netherlands), Centre for Agriculture and Biosciences international (CAB international, UK), Biosis Previews (USA), etc.